PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Symptom | C0153690|bone metastases |
| Sentences | 118 |
| PubMedID- 26237068 | Prevention and treatment of bone metastases in breast cancer. |
| PubMedID- 24069136 | Bisphosphonates are the current gold standard of care for breast cancer patients with bone metastases . |
| PubMedID- 22078026 | Recently, denosumab was compared to zoledronic acid in a phase iii randomized clinical trial in breast cancer patients with bone metastases . |
| PubMedID- 20530698 | Experimental design: nude rats bearing bone metastases after inoculation of mda-mb-231 breast cancer cells were treated with za (40 microg/kg weekly; n = 8 rats), sm (20 mg/kg daily; n = 8 rats), or their combination (za and sm; n = 8 rats) and compared with sham-treated controls (n = 10 rats). |
| PubMedID- 21936956 | Despite the completion of a randomized weekly low dose of zoledronic acid therapy study in breast cancer patients with bone metastases, no clear recommendation concerning its use outside of clinical studies can be given. |
| PubMedID- 22740794 | Treatment of bone metastases in patients with advanced breast cancer. |
| PubMedID- 22227259 | Conclusions: (18)f-fluoride-pet/mdct has higher diagnostic accuracy than (18)f-fluoride-pet/ct and mdct for the evaluation of bone metastases in breast cancer. |
| PubMedID- 23181392 | Analysis of orthopedic surgery of bone metastases in breast cancer patients. |
| PubMedID- 19484483 | Materials and methods: breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. |
| PubMedID- 20441435 | Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases. |
| PubMedID- 25724681 | Group i (n = 100) healthy females as a control group, group ii (n = 96) breast cancer patients without bone metastases, and group iii (n = 80) breast cancer patients with bone metastases. |
| PubMedID- 20200931 | (7) thus, although bisphosphonates maintain bone density in breast cancer patients with bone metastases and have been shown to increase disease-free survival in premenopausal patients with estrogen-responsive early breast cancer,(8) in animal models, bisphosphonates do not slow the growth of established lesions. |
| PubMedID- 25243101 | On the basis of a strong preclinical rationale, we used ra-223 dichloride to treat bone metastases in a patient with breast cancer. |
| PubMedID- 26237389 | Prevention of bone metastases in breast cancer patients. |
| PubMedID- 19918922 | A phase 2 trial exploring the effects of high-dose (10,000 iu/day) vitamin d(3) in breast cancer patients with bone metastases. |
| PubMedID- 24638849 | Recent studies have also implicated activin a in metastatic and osteoclastic processes , and plasma levels of activin a are higher in breast cancer patients with bone metastases as compared to those without, and positively correlate with bone metastatic burden . |
| PubMedID- 23801032 | Cd44−cd24+ cscs-like displayed a distinct bone tropism signature that was enriched in genes that discriminate bone metastases of breast cancer from metastases at other organs. |
| PubMedID- 20495798 | Conclusion: magnetic resonance imaging was found to be better than (18)fdg-pet and bs for diagnosis of bone metastases in patients with breast cancer on a per-patient basis. |
| PubMedID- 22335021 | Conclusion: our research cannot support the claim that tracp 5b could be useful as a diagnostic tool for the detection of bone metastases in patients with breast cancer. |
| PubMedID- 21461730 | breast cancer patients with bone metastases and sres have a poor prognosis compared to those with and without bone metastases regardless of cancer treatment or stage of disease at diagnosis. |
| PubMedID- 24924416 | We assessed whether vandetanib, an inhibitor of vegf, epidermal growth factor receptor and ret signalling, improved untx response when added to fulvestrant (f) in breast cancer patients with bone metastases. |
| PubMedID- 25257661 | Conclusion: wbs, spect and spect/ldct were less sensitive than mri and equally specific for the detection of bone metastases in patients with advanced breast cancer. |
| PubMedID- 24281036 | Elevated levels of serum postn have been reported in breast cancer patients presenting with bone metastases suggesting that postn could also be further investigated as a potential metastatic biomarker in the sera of escc patients . |
| PubMedID- 20798695 | We hypothesized that a crad armed with osteoprotegerin (opg) would eradicate bone metastases of breast cancer both directly, by oncolysis, and indirectly, by inhibiting osteoclastic bone resorption and thus reducing the tumor burden. |
| PubMedID- 23713047 | Conclusions: anti-hormonal therapy still seems to be considered as the ideal treatment of choice for postmenapousal breast cancer patients with isolated bone metastases. |
| PubMedID- 25884703 | The aim of our current analysis was to quantify the effects of rt on bone density in the metastatic bone in breast cancer patients with spinal bone metastases and to establish bone density as a marker for assessment of local response to rt. |
| PubMedID- 23576882 | We identified first-time breast cancer patients with bone metastases from 2003 through 2009 who had a subsequent sre (defined as pathologic fracture, spinal cord compression, radiation therapy, or surgery to bone). |
| PubMedID- 26587376 | Therefore, the prognostic and predictive effects of clinical and biochemical factors were examined in the aforementioned randomized study of a weekly low dose (metronomic arm) versus a conventional dosage of zoledronic acid (conventional arm) in breast cancer patients with bone metastases. |
| PubMedID- 25640386 | Significance of hormone receptor status in comparison of 18f -fdg-pet/ct and 99mtc-mdp bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience. |
| PubMedID- 24384612 | Recently, one study showed that plumbagin could inhibit bone metastases of breast cancer by modulating the tumor-bone microenvironment. |
| PubMedID- 21053109 | In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (sre; hr=0.82; p=0.01 superiority) and time to first and subsequent on-study sres (hr=0.77; p=0.001). |
| PubMedID- 23807419 | Bisphosphonates (bps) are in clinical use for the treatment of breast cancer patients with bone metastases. |
| PubMedID- 22969873 | The study comprised 16 breast cancer patients with painful multifocal bone metastases detected by bone scintigraphy, computed tomography or magnetic resonance imaging. |
| PubMedID- 21586099 | Denosumab is superior to bisphosphonate zoledronate in delaying time to first and subsequent skeletal-related events in breast cancer patients with bone metastases, demonstrating its potency as an antiresorptive agent . |
| PubMedID- 26273535 | Finally, preliminary data from guise24 indicate that the bone microenvironment adversely affects muscle in breast cancer patients with bone metastases, resulting in a chain of events that cause calcium leakage from muscle and resulting in muscle weakness. |
| PubMedID- 23311882 | Thus, breast cancer patients with bone metastases often have a poor prognosis4. |
| PubMedID- 23144574 | Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. |
| PubMedID- 21060033 | Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. |
| PubMedID- 21826964 | Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques. |
| PubMedID- 21814028 | In three phase iii trials, denosumab is superior to zoledronic acid, a potent bisphosphonate used as the standard therapy for bone metastases, for patients with prostate or breast cancers and is noninferior for patients with other solid tumors in terms of the median time to first on-study skeletal-related event. |
| PubMedID- 21779212 | In germany, the incidence of breast cancer patients with newly diagnosed bone metastases is approximately 11-12,000 cases. |
| PubMedID- 25114849 | Molecular pathogenesis of bone metastases in breast cancer: proven and emerging therapeutic targets. |
| PubMedID- 22740797 | breast cancer patients with bone metastases often suffer from cancer pain. |
| PubMedID- 21957430 | Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. |
| PubMedID- 22415590 | These drugs are used in instability of calcium homeostasis and for the palliation and prevention of bone metastases in patients with breast cancer and multiple myeloma. |
| PubMedID- 23344048 | Brain and bone metastases of breast cancer cells were compared by klein et al. |
| PubMedID- 22966289 | Due to their mechanism of action, bisphosphonates are expected to prevent the development of bone metastases in breast cancer patients. |
| PubMedID- 24558636 | In a large prospective study it was demonstrated that pthrp expression in primary breast cancer was significantly associated with less bone metastases . |
| PubMedID- 25191445 | (47) in their study of breast cancer in patients with bone metastases showed that 18f-fdgpet has the advantage of detecting osteolytic lesions; whereas, bone scintigraphy can detect osteoblastic lesions (48). |
| PubMedID- 23412771 | Role of breast surgery in t1-3 breast cancer patients with synchronous bone metastases. |